XIONG Yunyun, HUO Xiaochuan, JIA Baixue, PU Yuehua, LI Guangshuo, WANG Liyuan, CHENG Si, HAO Manjun, WANG Yongjun. Highlights in Stroke in 2022[J]. Chinese Journal of Stroke, 2023, 18(01): 1-16.
[1]SAVER J L，GOYAL M，VAN DER LUGT A，et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke：a meta-analysis[J]. JAMA，2016，316（12）：1279-1288.
[2]PÉREZ DE LA OSSA N，ABILLEIRA S，JOVIN T G，et al. Effect of direct transportation to thrombectomy-capable center vs local stroke center on neurological outcomes in patients with suspected large-vessel occlusion stroke in Nonurban Areas：the RACECAT randomized clinical trial[J]. JAMA，2022，327（18）：1782-1794.
[3]HUBERT G J，HUBERT N D，MAEGERLEIN C，et al. Association between use of a flying intervention team vs patient interhospital transfer and time to endovascular thrombectomy among patients with acute ischemic stroke in Nonurban Germany[J]. JAMA，2022，327（18）：1795-1805.
[4]ZACHRISON K S，SCHWAMM L H. Strategic opportunities to improve stroke systems of care[J]. JAMA，2022，327（18）：1765-1767.
[5]LOGALLO N，NOVOTNY V，ASSMUS J，et al. Tenecteplase versus alteplase for management of acute ischaemic stroke（NOR-TEST）：a phase 3，randomised，open-label，blinded endpoint trial[J]. Lancet Neurol，2017，16（10）：781-788.
[6]KVISTAD C E，NÆSS H，HELLEBERG B H，et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway（NOR-TEST 2，part A）：a phase 3，randomised，open-label，blinded endpoint，non-inferiority trial[J]. Lancet Neurol，2022，21（6）：511-519.
[7]MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[8]SANDSET E C，TSIVGOULIS G. Tenecteplase for acute ischaemic stroke[J]. Lancet，2022，400（10347）：138-139.
[9]YANG P，ZHANG Y，ZHANG L，et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med，2020，382（21）：1981-1993.
[10]ZI W Z，QIU Z M，LI F L，et al. Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke：the DEVT randomized clinical trial[J]. JAMA，2021，325（3）：234-243.
[11]SUZUKI K，MATSUMARU Y，TAKEUCHI M，et al. Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke：the SKIP randomized clinical trial[J]. JAMA，2021，325（3）：244-253.
[12]LECOUFFE N E，KAPPELHOF M，TREURNIET K M，et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke[J]. N Engl J Med，2021，385（20）：1833-1844.
[13]MITCHELL P J，YAN B，CHURILOV L，et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset：an open-label，blinded-endpoint，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：116-125.
[14]FISCHER U，KAESMACHER J，STRBIAN D，et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke：an open-label，blinded-outcome，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：104-115.
[15]KHATRI P. Intravenous thrombolysis before thrombectomy for acute ischaemic stroke[J]. Lancet，2022，400（10346）：76-78.
[16]GOYAL M，MENON B K，ZWAM W H，et al. Endovascular thrombectomy after large-vessel ischaemic stroke：a meta-analysis of individual patient data from five randomised trials[J]. Lancet，2016，387（10029）：1723-1731.
[17]ROMÁN L S，MENON B K，BLASCO J，et al. Imaging features and safety and efficacy of endovascular stroke treatment：a meta-analysis of individual patient-level data[J]. Lancet Neurol，2018，17（10）：895-904.
[18]DALKARA T，ARSAVA E M. Can restoring incomplete microcirculatory reperfusion improve stroke outcome after thrombolysis?[J]. J Cereb Blood Flow Metab，2012，32（12）：2091-2099.
[19]RENU A，MILLÁN M，SAN ROMÁN L，et al. Effect of intra-arterial alteplase vs placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke：the CHOICE randomized clinical trial[J]. JAMA，2022，327（9）：1-10.
[20]KHATRI P. Intra-arterial thrombolysis to target occlusions in distal arteries and the microcirculation[J]. IAMA，2022，327（9）：821-823.
[21]SARRAJ A，GROTTA J C，PUJARA D K，et al. Triage imaging and outcome measures for large core stroke thrombectomy - a systematic review and meta-analysis[J]. J Neurointerv Surg，2020，12（12）：1172-1179.
[22]YOSHIMURA S，SAKAI N，YAMAGAMI H，et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med，2022，386（14）：1303-1313.
[23]SCHWAMM L H. In stroke，when is a good outcome good enough?[J]. N Engl J Med，2022，386（14）：1359-1361.
[24]MEYER L，BROOCKS G. Endovascular therapy for large acute strokes[J]. N Engl J Med，2022，386（25）：2440.
[25]ZI W J，QIU Z M，WU D P，et al. Assessment of endovascular treatment for acute basilar artery occlusion via a nationwide prospective registry[J]. JAMA Neurol，2020，77（5）：561-573.
[26]TAO C R，QURESHI A I，YIN Y M，et al. Endovascular treatment versus best medical management in acute basilar artery occlusion strokes：results from the ATTENTION multicenter registry[J]. Circulation，2022，146（1）：6-17.
[27]JOVIN T G，LI C H，WU L F，et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1373-1384.
[28]TAO C R，NOGUEIRA R G，ZHU Y Y，et al. Trial of endovascular treatment of acute basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1361-1372.
[29]SCHONEWILLE W J. Favorable outcomes in endovascular therapy for basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1428-1429.
[30]STEEN W，GRAAF R A，CHALOS V，et al. Safety and efficacy of aspirin，unfractionated heparin，both，or neither during endovascular stroke treatment（MR CLEAN-MED）：an open-label，multicentre，randomised controlled trial[J]. Lancet，2022，399（10329）：1059-1069.
[31]ALMEKHLAFI M A，COUTTS S B. Anti-thrombotics cause harm in the setting of stroke thrombectomy[J]. Lancet，2022，399（10329）：1025-1026.
[32]HEO J H，LEE K Y，KIM S H，et al. Immediate reocclusion following a successful thrombolysis in acute stroke：a pilot study[J]. Neurology，2003，60（10）：1684-1687.
[33]CANNON C P，WEINTRAUB W S，DEMOPOULOS L A，et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban[J]. N Engl J Med，2001，344（25）：1879-1887.
[34]QIU Z M，LI F L，SANG H F，et al. Effect of intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke：the RESCUE BT randomized clinical trial[J]. JAMA，2022，328（6）：543-553.
[35]YANG P F，SONG L L，ZHANG Y W，et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke（ENCHANTED2/MT）：a multicentre，open-label，blinded-endpoint，randomised controlled trial[J]. Lancet，2022，400（10363）：1585-1596.
[36]MISTRY E A，NGUYEN T N. Blood pressure goals after mechanical thrombectomy：a moving target[J]. Lancet，2022，400（10363）：1558-1559.
[37]WEIR P，MAGUIRE R，O’SULLIVAN S E，et al. A meta-analysis of remote ischaemic conditioning in experimental stroke[J]. J Cereb Blood Flow Metab，2021，41（1）：3-13.
[38]ENGLAND T J，HEDSTROM A，O’SULLIVAN S，et al. RECAST（remote ischemic conditioning after stroke trial）：a pilot randomized placebo controlled phaseⅡtrial in acute ischemic stroke[J]. Stroke，2017，48（5）：1412-1415.
[39]HOU C B，LAN J，LIN Y N，et al. Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis（the RICA trial）：a multicentre，randomised，double-blind sham-controlled trial in China[J]. Lancet Neurol，2022，21（12）：1089-1098.
[40]GANESH A，SMITH E E，HILL M D. Remote ischaemic conditioning for stroke prevention[J]. Lancet Neurol，2022，21（12）：1062-1063.
[41]CHEN H S，CUI Y，LI X Q，et al. Effect of remote ischemic conditioning vs usual care on neurologic function in patients with acute moderate ischemic stroke：the RICAMIS randomized clinical trial[J]. JAMA，2022，328（7）：627-636.
[42]HESS D C，BLAUENFELDT R A，ANDERSEN G. Remote ischemic conditioning：feasible and potentially beneficial for ischemic stroke[J]. JAMA，2022，328（7）：622-624.
[43]DERDEYN C P，CHIMOWITZ M I，LYNN M J，et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis（SAMMPRIS）：the final results of a randomised trial[J]. Lancet，2014，383（9914）：333-341.
[44]GAO P，WANG T，WANG D M，et al. Effect of stenting plus medical therapy vs medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis：the CASSISS randomized clinical trial[J]. JAMA，2022，328（6）：534-542.
[45]BODEN W E，O’ROURKE R A，TEO K K，et al. Optimal medical therapy with or without PCI for stable coronary disease[J]. N Engl J Med，2007，356（15）：1503-1516.
[46]SEDLIS S P，HARTIGAN P M，TEO K K，et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease[J]. N Engl J Med，2015，373（20）：1937-1946.
[47]MARON D J，HOCHMAN J S，REYNOLDS H R，et al. Initial invasive or conservative strategy for stable coronary disease[J]. N Engl J Med，2020，382（15）：1395-1407.
[48]CHANG R W，TUCKER L Y，ROTHENBERG K A，et al. Incidence of ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA，2022，327（20）：1974-1982.
[49]STERPETTI A V，ARICI V，BOZZANI A. Ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA，2022，328（12）：1255-1256.
[50]HUANG K W，CHEN C W，WEI J C. Ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA，2022，328（12）：1256.
[51]SABATER-LLEAL M，HUANG J，CHASMAN D，et al. Multiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease[J]. Circulation，2013，128（12）：1310-1324.
[52]MALIK R，CHAUHAN G，TRAYLOR M，et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes[J]. Nat Genet，2018，50（4）：524-537.
[53]MISHRA A，MALIK R，HACHIYA T，et al. Stroke genetics informs drug discovery and risk prediction across ancestries[J]. Nature，2022，611（7934）：115-123.
[54]GALLEGO-FABREGA C，MUIÑO E，CÁRCEL-MÁRQUEZ J，et al. Genome-wide studies in ischaemic stroke：are genetics only useful for finding genes？[J]. Int J Mol Sci，2022，23（12）：6840.
